Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082146 · ClinicalTrials.gov registry record · Phase 1
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
A Phase 1 study of Pharmacokinetics and Metabolism, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01082146 is a Phase 1 study of Pharmacokinetics and Metabolism that has completed, run by Sumitomo Pharma America. The registered enrollment target is 6 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01082146, a Phase 1 study of Pharmacokinetics and Metabolism, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be an open-label, non-randomized, absorption, metabolism, and excretion study of Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a postprandial state
Conditions Studied
Interventions
- DRUG Lurasidone
Study Locations (1)
Wisconsin
- Covance Global Clinical Research Unit Inc. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082146
The ClinicalTrials.gov registry entry for NCT01082146 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (90% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Lurasidone is the first listed.
NCT01082146 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01082146 about?
NCT01082146 is a clinical study titled "RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE". This will be an open-label, non-randomized, absorption, metabolism, and excretion study of Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a postprandial state
What is the current status of trial NCT01082146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2008-08.
What conditions does trial NCT01082146 study?
This clinical trial studies the following conditions: Pharmacokinetics, Metabolism.
What interventions are being tested in trial NCT01082146?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01082146?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01082146 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.